Risedronic acid

Risedronic acid

Synthetic Approaches to Inhibitors of Isoprenoid Biosynthesis

Published in Peter Grunwald, Pharmaceutical Biocatalysis, 2019

Pedro Merino, Loredana Maiuolo, Ignacio Delso, Vincenzo Algieri, Antonio De Nino, Tomas Tejero

The use of phosphorous oxychloride was successfully extended to the synthesis of aledronate (6) and risedronic acid (9) (Grun et al., 2015a) without, however, good results in the synthesis of benzidronate (Grun et al., 2015b) in which phosphorous trichloride was the preferred reagent.

Can miR-34a be suitable for monitoring sensorineural hearing loss in patients with mitochondrial disease? A case series

View Article

Journal Information

Published in International Journal of Neuroscience, 2020

Roberta Marozzo, Valentina Pegoraro, Laura Dipietro, Massimo Ralli, Corrado Angelini, Arianna Di Stadio

Patient 1 was a 75 year-old man, affected by mitochondrial myopathy with multiple mitochondrial DNA (mtDNA) deletions, suffering from chronic obstructive pulmonary disease, hypertension, and Still disease. At the time of the study, the patient was being treated with corticosteroids (4 mg), rabeprazole (20 mg), idebenone (2700 mg), carnitine (2 g), alpha-lipoic acid (600 mg), oral supplement “Creatinine Plus” (1/die), tamsulosin (0.4 mg), verapamil chloralhydrate (180 mg), umeclidinium bromide (1 puff), beclomethasone (160 mg), formoterol (6 mg) (1 puff) and calcium carbonate and cholecalciferol (1 capsule). Also, the patient took 35 mg of Risedronic acid sodic salt weekly and 25.000 UI of vitamin D3 every 15 days. PTA showed a moderate to severe form of bilateral SNHL and normal impedance with bilateral absence of stapedius reflexes. The DPOAE test showed cochlear function impairment in the 1500-8000 Hz frequency range. ABR waves I and II were absent bilaterally, while waves III and V were normal.

Explore chapters and articles related to this topic

Synthetic Approaches to Inhibitors of Isoprenoid Biosynthesis

Can miR-34a be suitable for monitoring sensorineural hearing loss in patients with mitochondrial disease? A case series